Zyprexa Relprevv® (olanzapine)

LENGTH OF AUTHORIZATION: Maximum of six months

NOTES:
- Zyprexa Relprevv® is available only through a restricted distribution program. Zyprexa Relprevv® must not be dispensed directly to a patient. For a patient to receive treatment, the prescriber, healthcare facility, patient, and pharmacy must all be enrolled in the Zyprexa Relprevv® Patient Care Program (phone # 1-877-772-9390).

REVIEW CRITERIA:

1. Must have diagnosis of schizophrenia and

2. Age ≥ 18 years and

3. Must be prescribed by a provider that has enrolled in the Zyprexa Relprevv® Patient Care Program demonstrated with supporting documentation (signed attestation): [http://multivu.prnewswire.com/mnr/lilly/40089/docs/40089-ZyprexaRelprevvPatientCareProgramBackgrounder121409CLEAN(2).pdf](http://multivu.prnewswire.com/mnr/lilly/40089/docs/40089-ZyprexaRelprevvPatientCareProgramBackgrounder121409CLEAN(2).pdf)

4. Trial and failure of Risperdal Consta® or a recommendation from the first two bulleted statements below if applicable:
   - Hypersensitivity (allergy) or adverse response to oral olanzapine therapy is not a reason for approval. The provider should try other preferred oral antipsychotic agents or preferred long-acting injectables.
   - Ineffectiveness of oral olanzapine therapy is not a reason for approval. The provider should try other oral atypical antipsychotic agents. The provider should try other preferred oral antipsychotic agents or preferred long-acting injectables.
   - Failure of Risperdal Consta® is defined as an occurrence of intolerable adverse effect(s) (for example: constipation, extrapyrimadal symptoms (EPS), or cardiac events).
   - Failure may also be defined as “ineffectiveness of Risperdal Consta® therapy” if the patient has received a minimum of a one month trial on the optimal dose of 50 mg every 2 weeks. (This must be verified in claims history or progress notes).
CONTINUATION following ACUTE THERAPY:
- If the beneficiary has previously received Zyprexa Relprevv® as acute treatment (e.g., during institutionalization or hospitalization) and the provider is requesting continuation of therapy upon discharge:
  - If there is no trial history of Risperdal Consta® the request must be denied.
  - If there is trial of Risperdal Consta® (either in documentation or claims history) within the past 365 days refer to #3 of the review criteria.

CONTINUATION following CHRONIC THERAPY:
- The beneficiary must have documentation (e.g., paid prescription claims and documented administration history) of uninterrupted (100% compliance) Zyprexa Relprevv® therapy during the past 90 days and documented effectiveness.

DOSEING AND ADMINISTRATION:
- Establish tolerability with oral olanzapine prior to initiating treatment.
- There are no systematically collected data to specifically address how to switch patients with schizophrenia from other antipsychotics to Zyprexa Relprevv®. Refer to table below for recommendations on switching from oral olanzapine to Zyprexa Relprevv®:

<table>
<thead>
<tr>
<th>Target Oral Zyprexa® Dose</th>
<th>Dosing of Zyprexa Relprevv® During the First 8 Weeks</th>
<th>Maintenance Dose After 8 Weeks of Zyprexa Relprevv® Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mg/day</td>
<td>210 mg/2 weeks or 405 mg/4 weeks</td>
<td>150 mg/2 weeks or 300 mg/4 weeks</td>
</tr>
<tr>
<td>15 mg/day</td>
<td>300 mg/2 weeks</td>
<td>210 mg/2 weeks or 405 mg/4 weeks</td>
</tr>
<tr>
<td>20 mg/day</td>
<td>300 mg/2 weeks</td>
<td>300 mg/2 weeks</td>
</tr>
</tbody>
</table>

- Zyprexa Relprevv® is a powder for suspension for intramuscular use only. Zyprexa Relprevv® is present as a yellow solid in a glass vial equivalent to 210, 300, or 405 mg olanzapine per vial.